Anesthesia for Patients with Neurologic Disease: Intracranial and Spinal

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Cerebral Perfusion Pressure (CPP) Maintenance is Paramount: CPP is defined as Mean Arterial Pressure (MAP) minus Intracranial Pressure (ICP) or Central Venous Pressure. Anesthetic management must prioritize maintaining MAP at or above the lower limit of cerebral autoregulation (typically 60-70 mmHg in dogs, 60-80 mmHg in cats) to ensure adequate blood flow to the compromised central nervous system, especially when ICP is elevated.
• Carbon Dioxide and Temperature Control are Critical: Normocapnia (end-tidal CO2 35-45 mmHg) is essential as CO2 is a potent cerebral vasodilator; hypocapnia risks ischemia. Normothermia (37.0-38.0°C) is vital, as even 1°C deviations can significantly alter neurologic outcome after ischemia.
• Drug Selection Focuses on Cerebral Metabolic Effects: Agents that reduce cerebral metabolic rate for oxygen (CMRO2) and do not elevate ICP are preferred. Propofol reduces CMRO2 and ICP but has complex effects on neuronal apoptosis. Inhalant anesthetics (isoflurane, sevoflurane) reduce CMRO2 but can cause dose-dependent cerebral vasodilation, necessitating low MAC concentrations (<1.0-1.2 MAC) and adjunctive analgesia.
• Multimodal Analgesia and Careful Positioning are Essential: Opioids are crucial for pain management, preventing nociception-driven ICP increases, but require controlled ventilation. Positioning with head elevation (15-30 degrees) and a neutral neck promotes venous drainage without compromising jugular outflow.
• Rigorous Monitoring is Non-Negotiable: Continuous monitoring of MAP (invasive or oscillometric), end-tidal CO2 (capnography), temperature, pulse oximetry, and ECG is mandatory. Capnography is critical for ventilation adequacy and cerebral blood flow regulation, while frequent MAP assessment is vital to prevent hypotension-induced secondary injury.
• Preanesthetic Assessment and Risk Stratification are Comprehensive: A thorough neurologic examination establishes a baseline for monitoring intra- and postoperative changes. Imaging status dictates anesthetic strategy, with unconfirmed masses requiring a conservative approach assuming intracranial hypertension. Concurrent systemic conditions must be identified and factored into risk stratification.

This article addresses anesthetic planning and execution for small animal patients with intracranial or spinal disease. The intended reader is the practicing veterinarian who manages these cases in general or referral practice, whether for diagnostic imaging, biopsy, or surgical intervention. The clinical questions answered here concern how to preserve cerebral and spinal cord perfusion, how to avoid iatrogenic exacerbation of existing neurologic injury, and how to select and monitor anesthetic drugs in patients whose autoregulatory mechanisms may be impaired.

The principles that govern neuroanesthesia differ from routine anesthesia in one fundamental respect: the primary organ at risk is not the heart or lungs but the central nervous system itself. Patients with intracranial pathology have limited capacity to compensate for changes in cerebral blood flow, while patients with spinal cord injury face the threat of secondary injury from hypotension, hypoxemia, or malpositioning. The anesthetic plan must therefore be constructed around physiologic targets instead of drug availability alone.

At a Glance

Cerebral Physiology and the Injured Brain

Cerebral perfusion pressure (CPP) equals mean arterial pressure (MAP) minus intracranial pressure (ICP) or central venous pressure, whichever is higher. When intracranial compliance is reduced, small increases in intracranial volume produce large increases in ICP, and CPP falls even with a normal MAP. The brain normally autoregulates cerebral blood flow across a range of MAP values, but this range narrows or shifts after injury, and autoregulation may be regionally lost. The anesthetist must therefore treat MAP as a drug-titrated variable instead of a monitored afterthought.

Carbon dioxide is the dominant regulator of cerebral vascular tone. Hypercapnia produces cerebral vasodilation, increased cerebral blood volume, and rising ICP. Hypocapnia produces vasoconstriction and reduced cerebral blood flow, which can cause ischemia in already compromised tissue. The safe approach is to maintain normocapnia and reserve deliberate mild hyperventilation for acute deterioration with suspected herniation. Oxygenation must also be protected, since hypoxemia triggers cerebral vasodilation as a compensatory response.

Temperature exerts a powerful effect on neurologic outcome. In a canine model of complete cerebral ischemia, elevations of only 1 to 2 degrees C during the peri-ischemic period worsened functional recovery and histopathologic injury, while the same study demonstrated that even small temperature deviations must be actively controlled to interpret neurologic outcomes reliably. This finding supports rigorous perioperative temperature monitoring and active warming in all neuroanesthesia patients.

Anesthetic Drug Selection: Cerebral Metabolic Effects

The ideal neuroanesthetic agent reduces cerebral metabolic rate for oxygen (CMRO2), preserves or improves cerebral blood flow relative to metabolic demand, and does not elevate ICP. No single agent meets all criteria perfectly, and drug selection must account for the patient's cardiovascular reserve and the specific lesion type.

Propofol reduces CMRO2, cerebral blood flow, and ICP while preserving autoregulation and CO2 responsiveness. It also possesses antioxidant properties that may protect against ischemia-reperfusion injury in brain tissue. However, the evidence base includes concerning findings: propofol can superinduce the p75 neurotrophin receptor in injured neurons, promoting proapoptotic signaling, while simultaneously protecting astrocytes from oxidative stress. The net effect in the injured human or animal brain remains uncertain, and the literature acknowledges that neurologic recovery versus long-term neurodegeneration after propofol exposure is poorly understood. For clinical purposes, propofol remains a reasonable induction and maintenance choice for intracranial disease, but the anesthetist should recognize that its neuroprotective profile is not uniform across all cell types.

Inhalant anesthetics, particularly isoflurane and sevoflurane, reduce CMRO2 and are commonly used for maintenance. They cause dose-dependent cerebral vasodilation, which can increase cerebral blood volume and ICP in patients with reduced compliance. Keeping inhalant concentrations at or below 1.0 to 1.2 MAC, with adjunctive opioid analgesia, limits this effect. Nitrous oxide increases cerebral blood flow and CMRO2 and is generally avoided in intracranial disease.

Anesthetic Drug Selection: Systemic and Spinal Effects

Opioids provide analgesia without direct cerebral vasodilation and are valuable components of a balanced neuroanesthetic technique. They may cause respiratory depression, so ventilation must be controlled or closely monitored. The WSAVA Global Pain Council guidelines emphasize multimodal analgesia for all surgical patients, and the neuroanesthesia patient is no exception, provided hemodynamic stability is maintained.

Ketamine has historically been avoided in intracranial disease because of concern about increased cerebral blood flow and ICP. Contemporary evidence is more nuanced, but the drug's sympathomimetic effects can raise MAP and cerebral perfusion pressure in ways that are difficult to predict in the injured brain. When ketamine is used, it should be at low doses and with concurrent GABAergic agents.

For spinal disease, the same principles of perfusion maintenance apply. The spinal cord has less robust autoregulation than the brain, and it is particularly vulnerable to hypotension during positioning for dorsal laminectomy or hemilaminectomy. Neuraxial techniques such as epidural analgesia can provide excellent intraoperative and postoperative pain control, but they must be used cautiously in patients with spinal cord compression, where the volume of injectate could theoretically increase extradural pressure. Intrathecal midazolam has been studied in human cohorts and was not associated with increased neurologic symptoms, but the evidence base in veterinary patients is limited and this route is not standard practice.

Local Anesthetic Systemic Toxicity

Local anesthetics are used for infiltrative analgesia, nerve blocks, and neuraxial techniques in neurologic patients. Systemic toxicity presents most commonly with seizures, followed by cardiovascular collapse, and the presentation can be obscured by perioperative processes such as hypothermia, hypotension, or residual anesthetic effect. Risk is influenced by local anesthetic type, dose, volume, injection site, and patient comorbidities. A large-volume depot of dilute local anesthetic can take hours to reach peak plasma levels, so toxicity may appear well after the block is placed. Treatment priorities are oxygenation, ventilation, and advanced cardiac life support, with lipid emulsion therapy initiated at the first sign of serious toxicity. In the neurologic patient, a local anesthetic-induced seizure is particularly dangerous because it raises cerebral metabolic demand and ICP simultaneously.

Anesthetic Depth and Monitoring

Monitoring depth of anesthesia in neurologic patients requires integration of autonomic signs with the understanding that the neurologic examination is suppressed by the anesthetic itself. The AAHA Anesthesia and Monitoring Guidelines for Dogs and Cats recommend continuous assessment of ventilation, oxygenation, circulation, and temperature for all anesthetic patients, and these standards apply with particular force in neuroanesthesia. Capnography is essential, also to confirm endotracheal intubation but to maintain the targeted CO2 range. Direct or oscillometric blood pressure monitoring must be frequent enough to detect trends before they become crises.

The electroencephalogram is not routinely available in veterinary practice, but its principles inform clinical decision-making. Anesthetic agents that suppress cortical activity reduce cerebral metabolic demand, which is generally desirable in the injured brain. However, the same agents may mask seizure activity, and the anesthetist should maintain a low threshold for considering postoperative seizure prophylaxis in patients with known or suspected cortical lesions.

Positioning and Physiologic Support

Positioning for imaging or surgery must account for both the lesion and the patient's cardiovascular status. Head elevation of 15 to 30 degrees improves venous drainage and reduces ICP, but excessive elevation can lower cerebral perfusion pressure if MAP falls. The neck should be kept neutral to avoid jugular venous compression. For spinal surgery, the patient is often placed in sternal recumbency with the head elevated and the abdomen free from compression to avoid increased epidural venous pressure. Padding of all bony prominences and careful attention to limb positioning prevent peripheral nerve injury, which is a particular risk in patients who cannot reposition themselves during recovery.

Fluid therapy in neurologic patients should be directed at maintaining euvolemia and MAP without causing cerebral edema. Crystalloids are appropriate for maintenance and replacement, but large volumes of hypotonic solutions should be avoided. Hypertonic saline or mannitol may be indicated for acute intracranial hypertension, but these agents should be used based on measured or suspected ICP elevation instead of prophylactically.

Preanesthetic Assessment and Risk Stratification

The preanesthetic evaluation of a patient with intracranial or spinal disease must extend beyond the routine physical examination and laboratory screen. The neurologic examination establishes a baseline against which intraoperative and postoperative deterioration can be measured. Document mentation, postural reactions, spinal reflexes, and cranial nerve function before any sedative is administered. A patient with a brainstem lesion may have impaired gag or cough reflexes, which increases aspiration risk during induction and recovery. Cervical spinal disease may limit laryngeal mobility or pharyngeal function through lower motor neuron involvement.

Imaging status determines several anesthetic decisions. A patient with an unconfirmed intracranial mass requires a different induction strategy than one with a confirmed extra-axial lesion and known mass effect. If advanced imaging has not been performed, assume the worst case: intracranial hypertension with reduced compliance. The same principle applies to spinal disease. A patient with acute paraparesis and suspected intervertebral disc extrusion may have concurrent autonomic dysfunction, particularly if the lesion is T3 to L3. Bladder distension, bradycardia, and hypotension can all reflect loss of descending sympathetic tone.

Cardiovascular assessment deserves specific attention in patients with cervical spinal lesions. High cervical cord compression can produce vagal predominance and resting bradycardia. Conversely, pain from nerve root compression may drive tachycardia and hypertension. The anesthetist must distinguish these neurogenic patterns from primary cardiac disease. A focused echocardiogram is reasonable in older patients with murmurs, but it should not delay surgery in a patient with progressive neurologic signs.

Risk stratification should be communicated to the owner and the surgical team in explicit terms. The AAHA anesthesia and monitoring guidelines recommend assigning an ASA status and documenting the specific physiologic derangements that contribute to that status. For neurologic patients, the relevant derangements are not limited to the nervous system. Concurrent conditions such as hypovolemia from poor intake, aspiration pneumonia from dysphagia, or urinary tract infection from bladder dysfunction all modify anesthetic risk and should be listed individually.

Induction and Airway Management

The induction sequence for a patient with intracranial disease prioritizes three goals: avoid coughing and straining, maintain cerebral perfusion pressure, and secure the airway rapidly. Preoxygenation for three to five minutes increases the oxygen reserve and delays desaturation during apnea. The choice of induction agent matters less than the skill with which it is administered, provided the agent is titrated to effect and the airway is secured promptly.

Propofol reduces cerebral metabolic rate and intracranial pressure, and it has been studied for potential neuroprotective effects related to antioxidant activity in models of ischemia and traumatic brain injury Hausburg et al., institutional publication. However, propofol causes dose-dependent hypotension through vasodilation and myocardial depression, which can reduce cerebral perfusion pressure if mean arterial pressure falls. The same publication notes evidence of propofol toxicity in humans, including the rare propofol infusion syndrome, and acknowledges that the balance between neuroprotection and neurotoxicity in injured brain tissue remains incompletely understood. For clinical purposes, propofol is an acceptable induction agent in neurologic patients when combined with an opioid and when blood pressure support is immediately available.

Etomidate and alfaxalone are alternatives that produce less cardiovascular depression in most patients. The choice between these agents should be guided by the patient's cardiovascular status, the anesthetist's familiarity with the drug, and the availability of blood pressure support. No single agent is universally superior, and the MSD Veterinary Manual provides comparative pharmacology for these agents in dogs and cats.

Airway management requires anticipation of the difficult airway. Patients with brainstem lesions may have reduced jaw tone or impaired laryngeal reflexes. Patients with cervical spinal disease may resist neck extension, and excessive manipulation of the cervical spine risks further cord compression. Have a plan for alternative airway devices before induction. A video laryngoscope or a smaller endotracheal tube than usual may be needed. The endotracheal tube cuff should be inflated before the patient resumes spontaneous ventilation, and the tube should be secured without compressing the jugular veins.

Intraoperative Management: Blood Pressure and Perfusion Targets

The central intraoperative goal is maintenance of cerebral and spinal cord perfusion. Cerebral perfusion pressure equals mean arterial pressure minus intracranial pressure. When intracranial pressure is elevated, the only variable the anesthetist can control directly is mean arterial pressure. Hypotension is therefore more dangerous in the neurologic patient than in the healthy patient, and the threshold for intervention must be lower.

Set a minimum mean arterial pressure target before induction and communicate it to the entire team. A reasonable starting point is 60 to 70 mm Hg in dogs and 60 to 80 mm Hg in cats, adjusted for the patient's baseline blood pressure and species norms. Hypotension should be treated with intravenous fluids, vasopressors, or both. The choice depends on the presumed cause. Hypovolemia responds to fluid boluses. Vasodilation from anesthetic agents responds to vasopressors such as norepinephrine or vasopressin. Myocardial depression may require inotropic support. The AAHA anesthesia and monitoring guidelines emphasize that blood pressure monitoring should be continuous and that the monitoring method should be appropriate for the patient's size and condition.

Temperature management is a specific and often underestimated priority. A change of 1 degree Celsius in basal temperature significantly alters functional neurologic outcome and histopathology in a canine model of complete cerebral ischemia Wass et al., institutional publication. Hyperthermia worsens neurologic injury, while mild hypothermia may be protective. However, the same study demonstrates that the relationship is not linear and that temperature must be controlled within a narrow range. Active warming should begin before induction and continue through recovery. The target temperature is normothermia, approximately 37.0 to 38.5 degrees Celsius for dogs and 38.0 to 39.2 degrees Celsius for cats. Hyperthermia in the recovery period should be treated aggressively, but the anesthetist must distinguish fever from residual anesthetic effects or postoperative inflammation.

Monitoring Parameters and Their Interpretation

Capnography deserves special emphasis. End-tidal carbon dioxide directly influences cerebral blood flow through its effect on cerebrovascular resistance. Hypocapnia causes cerebral vasoconstriction and can reduce cerebral perfusion in patients with already compromised flow. Hypercapnia causes vasodilation and can increase intracranial pressure. The target range is generally 35 to 45 mm Hg, with lower values considered only in specific circumstances such as acute brain herniation. The AAHA anesthesia and monitoring guidelines list capnography as a required monitor for all anesthetized patients.

Documentation and Communication

The anesthetic record for a neurologic patient must capture more than vital signs. Document the baseline neurologic examination, the induction agent and its dose, the time from induction to intubation, and any episodes of hypotension, hypoxia, or hyperthermia. Record the patient's position, the duration of surgery, and the estimated blood loss. These details become critical if the patient deteriorates in the recovery period.

The recovery period is a continuation of the anesthetic event. Neurologic patients should be recovered in a quiet, warm environment with minimal stimulation. The anesthetist should remain with the patient until extubation and should document the return of consciousness, the presence or absence of voluntary movement, and the neurologic status at extubation. A patient who was ambulatory before surgery but cannot stand after recovery requires immediate evaluation for worsening of the underlying disease or a complication of anesthesia.

Communication with the owner should include a realistic description of the recovery trajectory. Some neurologic deficits improve slowly, and the immediate postoperative period may appear worse than the preoperative state. The WSAVA Global Pain Council Guidelines emphasize that pain assessment in neurologically impaired patients is challenging because the neurologic examination may mask or mimic pain behaviors. A multimodal analgesic plan should be in place before the patient emerges from anesthesia, and the response to analgesia should be documented separately from the neurologic assessment.

Recognized Complications and Early Detection

The most consequential failure modes in neuroanesthesia are those that silently elevate intracranial pressure (ICP) or reduce cerebral perfusion pressure (CPP) before vital signs deteriorate. Hypertension with bradycardia, the Cushing response, is a late sign of intracranial hypertension and should never be awaited as an early warning. The earliest indicators are trends, not single readings: progressive widening of the pulse pressure, rising end-tidal carbon dioxide despite unchanged minute ventilation, and a slow upward drift in mean arterial pressure (MAP) that resists deepening of anesthesia.

Hypotension is the more common and more dangerous failure. Cerebral autoregulation is impaired or abolished in regions of injury, so CPP follows MAP directly. A MAP that is acceptable for a healthy patient may be inadequate for a patient with a space-occupying lesion or recent spinal cord trauma. Detection requires an arterial catheter, oscillometric cuff readings lag during rapid change and become unreliable during hypotension or arrhythmia. The discriminating question when MAP falls is whether the cause is vasodilation, hypovolemia, or reduced cardiac output. A low or normal central venous pressure with a rapid response to a fluid bolus suggests hypovolemia. A falling end-tidal carbon dioxide with a rising heart rate points to reduced cardiac output. A stable or rising end-tidal carbon dioxide with a falling MAP suggests vasodilation, often from excessive inhalant depth.

Hypercapnia is the most readily preventable cause of secondary brain injury. Capnography detects it early, but the gradient between end-tidal and arterial carbon dioxide widens in low cardiac output states and in pulmonary disease. A patient with a normal end-tidal reading can still be hypercapnic. Arterial blood gas analysis is warranted whenever the clinical picture and capnography disagree.

Temperature derangements of even 1 degree C alter functional neurologic outcome and histopathology after cerebral ischemia in experimental models, with hyperthermia worsening injury and hypothermia conferring some protection Wass et al., canine model of complete cerebral ischemia. Core temperature must be measured continuously. Hyperthermia in the recovery period is particularly insidious because it is often attributed to postoperative inflammation when it actually represents ongoing neurologic injury.

Common Errors and Corrective Actions

Less experienced clinicians frequently underdose analgesics out of concern that opioids will mask neurologic assessment. This reasoning is flawed. Untreated pain raises cerebral metabolic rate, increases sympathetic outflow, and elevates ICP. The WSAVA Global Pain Council Guidelines support multimodal analgesia as a component of neuroprotective care. The corrective action is to treat pain aggressively and assess neurologic status at scheduled intervals instead of relying on the absence of pain as a surrogate for neurologic integrity.

A second recurring error is the assumption that a patient who is immobile is adequately anesthetized. Immobility can reflect muscle paralysis, profound sedation, or neurologic dysfunction instead of surgical depth. The corrective action is to use multiple depth indicators, including heart rate response to stimulation, tear production, jaw tone, and autonomic signs, and to document them at regular intervals.

A third error is delaying intubation in a patient with suspected raised ICP. The clinician may attempt to avoid the hypertensive response to laryngoscopy by waiting for deeper anesthetic depth, but this prolongs the period of airway instability and hypercapnia. The corrective action is to secure the airway promptly with a rapid, well-planned induction sequence and to blunt the intubation response with an appropriate adjunct.

Limitations of the Evidence

The evidence base for neuroanesthetic drug selection rests heavily on experimental models and human data. Propofol has demonstrated antioxidant and neuroprotective properties in animal models of ischemia-reperfusion and traumatic brain injury, but the same evidence identifies a rare propofol infusion syndrome and suggests that propofol may exacerbate neuronal apoptosis through p75 neurotrophin receptor signaling Hausburg et al., effects of propofol on ischemia-reperfusion and traumatic brain injury. The net clinical effect in dogs and cats with spontaneous neurologic disease remains uncertain.

The FDA warning on anesthesia and brain development addresses prolonged or repeated exposure to inhalational anesthetics, propofol, and midazolam in young children and third-trimester fetuses. Its relevance to veterinary patients is indirect, but it underscores that anesthetic agents are not neurologically inert and that duration of exposure should be minimized where clinically appropriate.

Expert opinion still differs on optimal MAP targets for spinal cord injury, on whether etomidate is acceptable for induction when cerebral perfusion is threatened, and on the value of routine intracranial pressure monitoring in veterinary patients. These disagreements reflect a genuine absence of outcome data. The AAHA Anesthesia and Monitoring Guidelines for Dogs and Cats provide a framework for monitoring but do not resolve these controversies.

Referral, Consultation, and Reporting

Referral to a specialist anesthesiologist or neurologist is warranted when a patient requires intracranial surgery, when preoperative imaging reveals significant mass effect or herniation, when a patient fails to regain consciousness within the expected time after anesthesia, or when refractory hypotension or intracranial hypertension develops intraoperatively. Specialist consultation is also appropriate when the clinician is uncertain whether a patient's neurologic status has deteriorated from the preanesthetic baseline.

Laboratory involvement is indicated when coagulopathy is suspected before neuraxial procedures, when electrolyte abnormalities could confound neurologic signs, and when arterial blood gas analysis is needed to interpret capnography. Regulatory reporting obligations vary by jurisdiction. The AVMA practice resources and WOAH terrestrial animal health standards describe reporting expectations for anesthetic deaths and adverse events, which in some regions must be documented even when no fault is apparent.

Frequently Asked Questions

How do I adjust my anesthetic plan when advanced monitoring equipment is unavailable?

When direct blood pressure measurement and capnography are absent, prioritize clinical surrogates and conservative drug choices. Palpate pulse quality, assess mucous membrane color, and monitor heart rate trends, but recognize these are late indicators of hypoperfusion. Use Doppler ultrasound for systolic pressure when available, as it outperforms palpation alone. Maintain spontaneous or assisted ventilation with frequent assessment of thoracic wall excursion and breath sounds. Choose agents with predictable cardiovascular profiles and titrate to effect using small incremental doses. The AAHA anesthesia and monitoring guidelines recommend that when full monitoring is impossible, the anesthetist must increase observation frequency and document limitations explicitly in the record.

What should I do when a patient deteriorates neurologically during recovery?

Recovery is a high-risk period for intracranial and spinal patients. Emergence excitement, coughing, and shivering raise intracranial pressure and threaten surgical sites. If neurologic status worsens, first assess oxygenation, ventilation, and perfusion. Check for hypothermia, which can mask consciousness, but avoid allowing fever, since temperature elevations of even 1 degree C worsen neurologic outcome after ischemic injury in experimental models. Reassess blood pressure, as hypotension reduces cerebral perfusion pressure while hypertension risks hemorrhage. If deterioration follows a clear temporal relationship to drug administration, consider residual sedation or opioid effects. When deterioration persists, evaluate for surgical complications such as hemorrhage or edema. The WSAVA pain management guidance supports using multimodal analgesia to reduce opioid requirements and associated sedation during recovery.

How do I manage anesthesia for a pregnant or very young patient with neurologic disease?

The FDA warning regarding anesthetic neurotoxicity applies to inhalational agents, propofol, and midazolam in third-trimester fetuses and children under three years, particularly for procedures exceeding three hours. This does not mean withholding necessary anesthesia, but it does argue for careful risk-benefit discussion and consideration of neuraxial techniques where feasible. For pediatric patients with intracranial disease, maintain normocapnia, normothermia, and stable blood pressure. Avoid hyperglycemia and hypoglycemia. For pregnant patients, preserve uterine perfusion by avoiding hypotension and aortocaval compression. The FDA warning analysis emphasizes balancing anesthetic benefits against potential developmental risks instead of avoiding anesthesia altogether.

What are the practical implications of local anesthetic systemic toxicity in spinal procedures?

Local anesthetic systemic toxicity presents most commonly as seizures, which can be mistaken for seizure activity from the primary neurologic disease. Risk increases with vascular injection, high total dose, and injection near highly vascularized tissue. Use the lowest effective concentration and volume, aspirate before injection, and administer incrementally. A large depot of dilute local anesthetic can reach peak plasma levels hours later, so monitoring must continue into the recovery period. Treatment priorities are oxygenation, ventilation, and seizure control, with lipid emulsion therapy at the first sign of serious toxicity. The local anesthetic systemic toxicity review notes that presenting signs are broad and can be obscured by perioperative processes, making a high index of suspicion essential.

How should I document anesthetic decisions and complications for neurologic patients?

Document the rationale for drug selection, particularly when choosing between agents with differing cerebral metabolic effects. Record baseline neurologic status, blood pressure targets, and any deviations from those targets with the corrective action taken. Note positioning details, including head elevation and padding. Document temperature at induction, throughout the procedure, and in recovery. If complications occur, record the timeline, interventions, and response. The AVMA practice resources emphasize that contemporaneous records support both clinical continuity and professional accountability. When referral is indicated, provide the receiving clinician with a summary that includes anesthetic drugs, doses, physiologic parameters, and any adverse events.

How do I explain anesthetic risk to an owner whose pet has a brain tumor or spinal injury?

Frame the discussion around the specific physiologic goals: maintaining blood flow to the injured nervous system, avoiding further injury from blood pressure swings, and managing pain without excessive sedation. Explain that anesthesia itself does not cure the neurologic disease but is required for diagnosis or treatment. Be honest about the increased risk compared with healthy patients, but avoid alarming language. Describe the monitoring that will be used and the contingency plans. The MSD Veterinary Manual provides accessible language for explaining neurologic disease and anesthetic risk to owners. Discuss cost implications of advanced monitoring and extended hospitalization before the procedure, and document that this discussion occurred.

Related Clinical & Scientific Guides

• Anesthetic Machine Leak Testing and Pressure Checks: A Step-by-Step Protocol
• Anesthetic Depth Assessment: Reflexes, Eye Position, and Ventilation
• Anesthesia for Patients with Obesity: Challenges and Solutions

References and Further Reading

• Effects of propofol on ischemia-reperfusion and traumatic brain injury.. 2020.
• Intrathecal midazolam I: a cohort study investigating safety.. 2004.
• Local Anesthetic Systemic Toxicity: A Narrative Literature Review and Clinical Update on Prevention, Diagnosis, and Management.. 2019.
• Temperature changes of > or = 1 degree C alter functional neurologic outcome and histopathology in a canine model of complete cerebral ischemia.. 1995.
• Food and Drug Administration warning on anesthesia and brain development: implications for obstetric and fetal surgery.. 2018.
• Histopathologic correlation of magnetic resonance imaging signal patterns in a spinal cord injury model.. 1990.
• AAHA Anesthesia and Monitoring Guidelines for Dogs and Cats. AAHA.
• WSAVA Global Pain Council Guidelines. WSAVA.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Anesthesia for Patients with Dental Disease: Extractions and Cleaning
• Anesthesia for Patients with Ear Disease: Vestibular Syndrome
• Anesthesia for Patients with Endocrine Disease: Diabetes and Hyperthyroidism
• Anesthesia for Patients with Gastrointestinal Disease: Aspiration Risk
• Anesthesia for Patients with Hematologic Disease: Coagulopathy and Anemia

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.